Supplemental Figure 1:

Cumulative incidence of outcomes for tertiles of SUA levels in the placebo arm of the EMPEROR-reduced study cohort: (A) composite primary endpoint (first HHF or CV death), (B) first HHF, (C) CV death

A

Patients at risk

<T1	573	534	516	436	353	281	194	126	65	28
≥T1 and <T2	641	603	566	480	399	306	215	149	78	31
≥T2	628	556	511	413	344	257	193	127	78	48

B

Patients at risk

<T1	573	534	516	436	353	281	194	126	65	28
≥T1 and <T2	641	603	566	480	399	306	215	149	78	31
≥T2	628	556	511	413	344	257	193	127	78	48

C

Patients at risk

<T1	573	561	550	479	398	322	226	155	84	37
≥T1 and <T2	641	630	612	534	457	362	252	174	94	45
≥T2	628	609	584	500	423	330	254	168	101	54